Rodrigues Pessoa R, Nabavizadeh R, Shah P, Frank I, Tollefson M, Sharma V et al. Relative Impact of Lymph-node Metastasis and Seminal Vesical Invasion on. Oncologic Outcomes Following Radical Prostatectomy. Prostate Cancer Prostatic Dis 2023. https://doi.org/10.1038/s41391-023-00724-9.

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7.

Article  CAS  PubMed  Google Scholar 

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66. https://doi.org/10.1016/S0140-6736(18)32486-3.

Article  PubMed  PubMed Central  Google Scholar 

Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Wiegel T, et al. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2021;39:2284–93. https://doi.org/10.1200/JCO.20.03714.

Article  CAS  PubMed  Google Scholar 

Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Mohamad O, et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. JCO. 2023;41:2428–35. https://doi.org/10.1200/JCO.22.02489.

Article  CAS  Google Scholar 

Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, et al. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. Eur Urol Oncol. 2020;3:565–81. https://doi.org/10.1016/j.euo.2020.08.005.

Article  PubMed  Google Scholar 

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60. https://doi.org/10.1016/S0140-6736(21)02437-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Touijer KA, Sjoberg DD, Benfante N, Laudone VP, Ehdaie B, Eastham JA, et al. Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial. Eur Urol Oncol. 2021;4:532–9.

Article  PubMed  PubMed Central  Google Scholar 

Lestingi JFP, Guglielmetti GB, Trinh QD, Coelho RF, Pontes J Jr, Bastos DA, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol. 2021;79:595–604.

Article  PubMed  Google Scholar